214 related articles for article (PubMed ID: 11522576)
1. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis.
Leib SL; Clements JM; Lindberg RL; Heimgartner C; Loeffler JM; Pfister LA; Täuber MG; Leppert D
Brain; 2001 Sep; 124(Pt 9):1734-42. PubMed ID: 11522576
[TBL] [Abstract][Full Text] [Related]
2. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex.
Meli DN; Loeffler JM; Baumann P; Neumann U; Buhl T; Leppert D; Leib SL
J Neuroimmunol; 2004 Jun; 151(1-2):6-11. PubMed ID: 15145598
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.
Leib SL; Leppert D; Clements J; Täuber MG
Infect Immun; 2000 Feb; 68(2):615-20. PubMed ID: 10639424
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor.
Clements JM; Cossins JA; Wells GM; Corkill DJ; Helfrich K; Wood LM; Pigott R; Stabler G; Ward GA; Gearing AJ; Miller KM
J Neuroimmunol; 1997 Apr; 74(1-2):85-94. PubMed ID: 9119983
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone regulation of matrix metalloproteinase expression in experimental pneumococcal meningitis.
Liu X; Han Q; Sun R; Li Z
Brain Res; 2008 May; 1207():237-43. PubMed ID: 18374903
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis.
Liechti FD; Grandgirard D; Leppert D; Leib SL
Infect Immun; 2014 Apr; 82(4):1710-8. PubMed ID: 24491581
[TBL] [Abstract][Full Text] [Related]
7. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis.
Redford EJ; Smith KJ; Gregson NA; Davies M; Hughes P; Gearing AJ; Miller K; Hughes RA
Brain; 1997 Oct; 120 ( Pt 10)():1895-905. PubMed ID: 9365379
[TBL] [Abstract][Full Text] [Related]
8. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing.
DiMartino M; Wolff C; High W; Stroup G; Hoffman S; Laydon J; Lee JC; Bertolini D; Galloway WA; Crimmin MJ; Davis M; Davies S
Inflamm Res; 1997 Jun; 46(6):211-5. PubMed ID: 9243304
[TBL] [Abstract][Full Text] [Related]
9. Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis.
Muri L; Grandgirard D; Buri M; Perny M; Leib SL
J Neuroinflammation; 2018 Aug; 15(1):233. PubMed ID: 30131074
[TBL] [Abstract][Full Text] [Related]
10. Effect of a matrix metalloproteinase activity and TNF-alpha converting enzyme inhibitor on intra-abdominal adhesions.
Mirastschijski U; Johannesson K; Jeppsson B; Agren MS
Eur Surg Res; 2005; 37(1):68-75. PubMed ID: 15818044
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant TACE inhibitor treatment improves the outcome of TLR2-/- mice with experimental pneumococcal meningitis.
Echchannaoui H; Leib SL; Neumann U; Landmann RM
BMC Infect Dis; 2007 Apr; 7():25. PubMed ID: 17428319
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases.
Conway JG; Andrews RC; Beaudet B; Bickett DM; Boncek V; Brodie TA; Clark RL; Crumrine RC; Leenitzer MA; McDougald DL; Han B; Hedeen K; Lin P; Milla M; Moss M; Pink H; Rabinowitz MH; Tippin T; Scates PW; Selph J; Stimpson SA; Warner J; Becherer JD
J Pharmacol Exp Ther; 2001 Sep; 298(3):900-8. PubMed ID: 11504783
[TBL] [Abstract][Full Text] [Related]
13. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases.
Matyszak MK; Perry VH
J Neuroimmunol; 1996 Sep; 69(1-2):141-9. PubMed ID: 8823386
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
15. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
Kottirsch G; Koch G; Feifel R; Neumann U
J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of TNF-alpha convertase (TACE/ADAM17) after oxygen-glucose deprivation in rat forebrain slices.
Hurtado O; Cárdenas A; Lizasoain I; Boscá L; Leza JC; Lorenzo P; Moro MA
Neuropharmacology; 2001 Jun; 40(8):1094-102. PubMed ID: 11406201
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats.
Barichello T; Generoso JS; Michelon CM; Simões LR; Elias SG; Vuolo F; Comim CM; Dal-Pizzol F; Quevedo J
Exp Biol Med (Maywood); 2014 Feb; 239(2):225-31. PubMed ID: 24419461
[TBL] [Abstract][Full Text] [Related]
18. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
[TBL] [Abstract][Full Text] [Related]
19. Effect of a matrix metalloproteinase inhibitor (BB-1101) on nerve regeneration.
Demestre M; Gregson NA; Smith KJ; Miller KM; Gearing AJ; Hughes RA
Ann N Y Acad Sci; 1999 Jun; 878():658-61. PubMed ID: 10415800
[No Abstract] [Full Text] [Related]
20. Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats.
Vyavahare N; Jones PL; Tallapragada S; Levy RJ
Am J Pathol; 2000 Sep; 157(3):885-93. PubMed ID: 10980128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
